![Responding to Omicron: Aggressively Increasing Booster Vaccinations Now Could Prevent Many Hospitalizations and Deaths | Commonwealth Fund Responding to Omicron: Aggressively Increasing Booster Vaccinations Now Could Prevent Many Hospitalizations and Deaths | Commonwealth Fund](https://www.commonwealthfund.org/sites/default/files/responding-to-omicron-aggressively-increasing-booster-vaccinations-now-could-prevent-many-hospitalizations-and-deaths-exhibit-2.png)
Responding to Omicron: Aggressively Increasing Booster Vaccinations Now Could Prevent Many Hospitalizations and Deaths | Commonwealth Fund
![Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland | The University of Edinburgh Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland | The University of Edinburgh](https://www.ed.ac.uk/sites/default/files/styles/landscape_breakpoints_theme_uoe_mobile_1x/public/thumbnails/image/v.6_omicron.png?itok=ZFbrm-WP)
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland | The University of Edinburgh
![Sputnik V on X: "Canadian real-world study of mRNA vaccines efficiency vs # Omicron shows negative efficacy of 2 mRNA doses and quickly waning efficiency of homologous #mRNA booster: “A third dose provides Sputnik V on X: "Canadian real-world study of mRNA vaccines efficiency vs # Omicron shows negative efficacy of 2 mRNA doses and quickly waning efficiency of homologous #mRNA booster: “A third dose provides](https://pbs.twimg.com/media/FIPiC5yXoAYJFaO.jpg)
Sputnik V on X: "Canadian real-world study of mRNA vaccines efficiency vs # Omicron shows negative efficacy of 2 mRNA doses and quickly waning efficiency of homologous #mRNA booster: “A third dose provides
Eric Topol on X: "First data on booster vaccine effectiveness vs Omicron (581 cases): drop in protection vs symptomatic infection by 2 doses (AZ ->0, Pfizer-> <40%) restored to ~75% with 3rd
![Vaccines | Free Full-Text | COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects Vaccines | Free Full-Text | COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects](https://www.mdpi.com/vaccines/vaccines-10-01223/article_deploy/html/images/vaccines-10-01223-g001.png)
Vaccines | Free Full-Text | COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
![Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What](https://www.mdpi.com/vaccines/vaccines-10-01924/article_deploy/html/images/vaccines-10-01924-g001.png)
Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What
![Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/figures/mm7118a4-F-large.gif?_=74292)
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR
![Efficacy of booster messenger ribonucleic acid COVID-19 vaccinations against SARS-CoV-2 Omicron variant severity Efficacy of booster messenger ribonucleic acid COVID-19 vaccinations against SARS-CoV-2 Omicron variant severity](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_730120_16675737040107484.jpg)
Efficacy of booster messenger ribonucleic acid COVID-19 vaccinations against SARS-CoV-2 Omicron variant severity
Eric Topol on X: "The decline of vaccine effectiveness vs Omicron. Simplified (no 95% CI) summary for Pfizer vaccine vs Delta, + booster, and vs Omicron, + booster (early @UKHSA data) vs
![Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12–17 years in Singapore: a national cohort study - The Lancet Infectious Diseases Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12–17 years in Singapore: a national cohort study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/21aefd8d-1880-42db-8338-92a386a5842f/gr1.jpg)
Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12–17 years in Singapore: a national cohort study - The Lancet Infectious Diseases
![Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study | The BMJ Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study | The BMJ](https://www.bmj.com/content/bmj/378/bmj-2022-071502/F2.large.jpg)
Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study | The BMJ
![COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents - eBioMedicine COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents - eBioMedicine](https://www.thelancet.com/cms/asset/be95fd01-303d-485d-806b-6d494baf486e/gr1.jpg)